Antibiotic consumption in Europe, 2019–2024: Being AWaRe is not about using less

Abstract

OBJECTIVES: Antimicrobial consumption surveillance is central to strategies addressing antimicrobial resistance (AMR), yet indicators for benchmarking national performance remain debated. We evaluated whether applying the WHO Access, Watch and Reserve (AWaRe) classification provides a more meaningful assessment of antimicrobial stewardship than conventional defined daily dose (DDD)-based metrics. METHODS: European antimicrobial consumption surveillance data from 2019 to 2024 were examined to compare country performance using conventional DDD-based indicators and Access-based metrics. Country rankings were interpreted in relation to antimicrobial resistance epidemiology and AMR-attributable mortality, and the strenghts and limitations of each surveillance approach were assessed. RESULTS: Application of the AWaRe classification substantially reshaped country rankings compared with DDD-based metrics and showed closer alignment with resistance epidemiology and AMR-attributable mortality. Countries with higher proportions of Access-group antibiotics, rather than lower overall antimicrobial consumption, demonstrated more favourable stewardship profiles. DDD-based indicators may underestimate appropriate prescribing practices, including high-dose short-course regimens and early intravenous-to-oral switch strategies, as illustrated by examples from the United Kingdom and Japan. CONCLUSIONS: AWaRe should be considered a stewardship and governance tool rather than a punitive performance indicator and interpreted alongside antimicrobial resistance data, case mix, and clinical outcomes. Integrating risk-stratified, outcome-informed indicators into surveillance frameworks may better support antimicrobial stewardship policies, harmonize benchmarking across Europe, and improve strategies to reduce AMR.

Assessing food consumption discrepancy between food balance sheet and survey dietary data in Europe
Silvestre García de Jalón, Luis Garrote, Simona Castaldi +2
Food and Humanity9 Oct 2026Peer-reviewedLicence not stated1 citedGeneral biology NutritionHAL
Knowledge and attitudes toward antimicrobial stewardship and the WHO AWaRe antibiotic classification among healthcare professionals at a tertiary hospital in Ethiopia
Tamrat Assefa Tadesse, Sumeya Sani, Melaku Tileku Tamiru +1
Scientific Reports21 Oct 2026Peer-reviewedCC BY-NC-ND 4.0Full textMicrobiologyCrossref
Burden of bacterial antimicrobial resistance associated with modifiable human antibiotic consumption: An observational study
Benjamin J. Singer, Alec Gleason, Isabella Impalli +6
PLOS Medicine26 Oct 2026Peer-reviewedCC BY 4.0Full textMicrobiology Epidemiology & public healthPLOSPMC
Patterns and potential indications of WHO AWaRe Watch antibiotic use across UK community and hospital care: a national observational study.
Elin J Rowlands, Cecilia Campanile, Hiba Junaid +28
European journal of public health1 Oct 2026Peer-reviewedCC BYFull textMicrobiologyEurope PMCPMC
Bernard was right about the placenta
Emmanuel Drouin, Yann Péréon
The Journal of Physiology3 Jun 2026Peer-reviewedLicence not statedFull textGeneral biologyHAL

Cite

BibTeX RIS

BibTeX

@article{leroux2026antibiotic,
  title = {{Antibiotic consumption in Europe, 2019–2024: Being AWaRe is not about using less}},
  author = {Pierre Leroux and Didier Lepelletier and Delphine Merillon and Louise Rouillard and Maelys Durand and Marie Fuentes-Braesch and Benjamin Davido},
  journal = {International Journal of Antimicrobial Agents},
  year = {2026},
  month = oct,
  doi = {10.1016/j.ijantimicag.2026.107890},
  url = {https://amu.hal.science/hal-05829936v1},
  note = {CC BY},
}

RIS

TY  - JOUR
TI  - Antibiotic consumption in Europe, 2019–2024: Being AWaRe is not about using less
AU  - Pierre Leroux
AU  - Didier Lepelletier
AU  - Delphine Merillon
AU  - Louise Rouillard
AU  - Maelys Durand
AU  - Marie Fuentes-Braesch
AU  - Benjamin Davido
PY  - 2026
DA  - 2026/10/21
JO  - International Journal of Antimicrobial Agents
DO  - 10.1016/j.ijantimicag.2026.107890
UR  - https://amu.hal.science/hal-05829936v1
AB  - OBJECTIVES: Antimicrobial consumption surveillance is central to strategies addressing antimicrobial resistance (AMR), yet indicators for benchmarking national performance remain debated. We evaluated whether applying the WHO Access, Watch and Reserve (AWaRe) classification provides a more meaningful assessment of antimicrobial stewardship than conventional defined daily dose (DDD)-based metrics. METHODS: European antimicrobial consumption surveillance data from 2019 to 2024 were examined to compare country performance using conventional DDD-based indicators and Access-based metrics. Country rankings were interpreted in relation to antimicrobial resistance epidemiology and AMR-attributable mortality, and the strenghts and limitations of each surveillance approach were assessed. RESULTS: Application of the AWaRe classification substantially reshaped country rankings compared with DDD-based metrics and showed closer alignment with resistance epidemiology and AMR-attributable mortality. Countries with higher proportions of Access-group antibiotics, rather than lower overall antimicrobial consumption, demonstrated more favourable stewardship profiles. DDD-based indicators may underestimate appropriate prescribing practices, including high-dose short-course regimens and early intravenous-to-oral switch strategies, as illustrated by examples from the United Kingdom and Japan. CONCLUSIONS: AWaRe should be considered a stewardship and governance tool rather than a punitive performance indicator and interpreted alongside antimicrobial resistance data, case mix, and clinical outcomes. Integrating risk-stratified, outcome-informed indicators into surveillance frameworks may better support antimicrobial stewardship policies, harmonize benchmarking across Europe, and improve strategies to reduce AMR.
SN  - 0924-8579
SN  - 1872-7913
ER  -

Abstract

Related

Cite